Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials - Top-Institutions - MDSpire

Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials

  • By

  • Jingyi Li

  • Yemin Xu

  • Lu Wang

  • Ying Zhu

  • Bin Deng

  • June 19, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #3

    Massachusetts General Hospital Cancer Center
    Massachusetts General Hospital Cancer Center

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

  • #5

    David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLA

    Los Angeles, CA

    Key Differentiators

    • Oncology

Original Source(s)

Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials

  • by Jingyi Li, Yemin Xu, Lu Wang, Ying Zhu, Bin Deng

  • June 19, 2026

Related Content

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

Effects of surgery on cancer metastasis: biological mechanisms and perioperative implications